Keyword: Allergan

Too-snug jeans in the back of the closet? Allergan’s newest spokescelebrity can relate, and she's talking about her CoolSculpting story.

A top pharma CEO says President Trump is right to say other countries benefit from higher U.S. drug prices, but he’s not sold on proposals for a fix.

With generics expected soon for eye drug Restasis, Allergan has canceled a $200 million expansion at its Waco, Texas, manufacturing plant.

Growth for Allergan and Ironwood’s Linzess is easing up, and one analyst thinks Allergan may not be part of the solution.

Earlier this year, Pfizer struck out on a sale of its consumer health unit. But it may be ready to try its hand at another selloff.

Allergan's efforts to shed its women’s health and infectious disease units aren’t progressing quite as well as CEO Brent Saunders had hoped.

Big biopharma CEOs gave most or all their campaign contributions to Republicans this season, but one went full blue with his $120,000.

Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market.

Allergan and Eli Lilly won coverage from PBM giant Express Scripts for their new migraine launches, but Teva's Ajovy was left out in the cold.